NCT06887023 is a clinical trial in Bile Duct Neoplasms Malignant, sponsored by The First Hospital of Jilin University.

Who is sponsoring NCT06887023?

NCT06887023 is sponsored by The First Hospital of Jilin University.

What condition does NCT06887023 study?

NCT06887023 studies Bile Duct Neoplasms Malignant.

Is NCT06887023 still recruiting?

NCT06887023 is currently completed. Last updated 20 March 2025.

Last reviewed 2025-03-20 · How we verify

NCT06887023

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinicopathologic Characteristics, Progression, and Prognostic Analysis of IPNB

Completed Last updated 20 March 2025

What this trial tests

trial in Bile Duct Neoplasms Malignant in 118 participants. Completed in 1 February 2025.

Timeline

1 December 2024

Primary endpoint
15 January 2025

1 February 2025

Quick facts

Lead sponsor	The First Hospital of Jilin University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	118
Start date	1 December 2024
Primary completion	15 January 2025
Estimated completion	1 February 2025
Sites	1 location across China

Conditions studied

Bile Duct Neoplasms Malignant — all drugs for Bile Duct Neoplasms Malignant →

Sponsor

The First Hospital of Jilin University

Who can join

Eligibility, any sex, with Bile Duct Neoplasms Malignant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this observational study is to understand the clinicopathological and prognostic information of IPNB, a rare tumor. The participants have already received treatment during their previous routine medical management and took part in follow - up. We will look into their survival information after previous medical visits and treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other The First Hospital of Jilin University trials

Trials by the same sponsor.

NCT07308340 — Rapid Identification of Infectious Pathogens in Severe Pneumonia Guided by Bronchoscopic Imaging and Lung CT · not yet recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07414160 — Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients · not yet recruiting
NCT07440368 — Enterocyte Injury and Acute Gastrointestinal Dysfunction in Critical Illness · not yet recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06887023 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Hospital of Jilin University
Last refreshed: 20 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06887023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing